|
DAY 1 | Monday March 10th 2008
|
|
Morning plenary session
Addressing the productivity crunch and fostering sustained product innovation: How is scale impacting performance?
|
FOLLOWED BY YOUR CHOICE OF 3 PARALLEL SESSIONS:
|
|
Focus session 1
|
OR | Focus session 2
|
OR | Workshop
|
Making decisions on strategic directions for new modalities and new therapeutic areas: Finding value in primary care, speciality care and biologics
|
Translational medicine: What is the progress with implementation and what are the first signs of ROI?
|
Biotech business models: Is the model for engagement with pharma still dominated by M&A or are new opportunities for collaboration emerging?
|
|
THEN | Afternoon plenary session
Panel discussion
Crossing the chasm between science and business: Progress with end-to-end initiatives that deliver seamless integration
|
|
|
|
| DAY 2 | Tuesday March 11th 2008 |
|
Morning plenary session
How does each stakeholder group assess value, benefit and risk and decide what is acceptable? How should R&D respond?
|
FOLLOWED BY YOUR CHOICE OF 3 PARALLEL SESSIONS:
|
|
Focus session 1
|
OR | Focus session 2
|
OR | Workshop |
|
Assessing recent progress in the early prediction of safety
|
Transforming discovery research by stepping up collaboration within biopharma, and externally via academia and public/private partnerships
|
Optimizing late stage clinical trials to capitalize on opportunities for product differentiation and value creation pre-licensure
|
THEN | Afternoon plenary session
Identifying and developing qualified leaders to manage the transformation of R&D |
|
|
DAY 3 | Wednesday March 12th 2008
|
|
Morning plenary session
Decentralisation, offshoring and globalization: Where and how is biopharma generating greatest value?
|
